Oxford Genome Sciences has appointed Mike Gresser to its scientific advisory board, the company said last week. Gresser is currently a visiting scholar at the Molecular Biology Institute at the University of California, Los Angeles.
He served before that as executive director of biochemistry and molecular biology at the Merck Frost Center for Therapeutic Research in Quebec.
SensiGen last week said it has named Nicholas Kefalides to the company’s scientific advisory board.
Kefalides was a professor at the University of Pennsylvania for 26 years, and retired from the school in 2006 as professor emeritus.
The company said Kefalides has since been involved in teaching, research, and writing about his area of expertise: the role of connective tissues and basement membranes in degenerative and infectious diseases.
Stem Cell Innovations has named Ian Lyons chief scientific officer, US, the company said last week.
Lyons was previously research area manager, stem cells, and principal scientist for Invitrogen. Prior to this, he was employed in a variety of positions at BresaGen. He holds a PhD from the University of Melbourne.